Clinical Trial Update: Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants [Phase 3]

View source ↗

Summary

A Phase 3 trial completed to evaluate the safety and immunogenicity of a live attenuated mumps vaccine in healthy infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mumps

Drugs mentioned

• Live attenuated mumps vaccine (mumps vaccine, live attenuated)

Snippet

Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Conditions: Mumps | Phase 3 | Status: COMPLETED